抗体偶联药物在非小细胞肺癌中的应用  

Application of antibody-drug conjugates in the treatment of non-small cell lung cancer

作　　者：张静娴 易丹[1] 李小江[1] Zhang Jingxian;Yi Dan;Li Xiaojiang(Department of Oncology,First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion,Tianjin 300380,China)

机构地区：[1]天津中医药大学第一附属医院肿瘤科国家中医针灸临床医学研究中心,天津300380

出　　处：《国际肿瘤学杂志》2022年第5期296-301,共6页Journal of International Oncology

基　　金：中华国际医学交流基金(Z-2014-06-2102)。

摘　　要：抗体偶联药物(ADC)以其抗体靶向性的独特优势,克服了传统化疗和靶向治疗的局限性,并在肺癌治疗领域取得了突破性的成绩。目前ADC在非小细胞肺癌中的研究主要涉及靶点有HER2、HER3、TROP2、MET、CEACAM5,多种药物已通过严格的临床试验,并表现出良好的安全性和有效性,为肺癌个性化治疗提供了理论依据。Antibody-drug conjugates(ADCs)have overcome the limitations of traditional chemotherapy and targeted therapy with unique advantage of antibody targeting,and made breakthrough achievements in the treatment of lung cancer.At present,the researches of ADCs in non-small cell lung cancer mainly involve HER2,HER3,TROP2,MET,CEACAM5.Many ADCs have passed rigorous clinical trials,and have shown good safety and efficacy,which provides theoretical basis for individualized treatment of lung cancer.

关 键 词：抗体 细胞毒素类 肺肿瘤 分子靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]